TfR (Transferrin R) Antibody (OX26) - BSA Free

Flow Cytometry: TfR (Transferrin R) Antibody (OX26) - BSA Free [NB200-585]

Flow Cytometry: TfR (Transferrin R) Antibody (OX26) [NB200-585] - Analysis using the Biotin conjugate of NB200-585. Staining of mouse spleen.

Flow Cytometry: TfR (Transferrin R) Antibody (OX26) - BSA Free [NB200-585]

Flow Cytometry: TfR (Transferrin R) Antibody (OX26) [NB200-585] - Staining of rat spleen lymphocytes with mouse anti rat CD71.

Flow (Intracellular): TfR (Transferrin R) Antibody (OX26) - BSA Free [NB200-585]

Flow (Intracellular): TfR (Transferrin R) Antibody (OX26) [NB200-585] - PC-12 cells were stained with NB200-585 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 1 ug/mL for 30 minutes at room temperature, followed by DyLight488-conjugated anti-mouse secondary antibody.

Flow Cytometry: TfR (Transferrin R) Antibody (OX26) - BSA Free [NB200-585]

Flow Cytometry: TfR (Transferrin R) Antibody (OX26) [NB200-585] - Staining of rat spleen cells with mouse anti rat CD71: RPE.

Flow Cytometry: TfR (Transferrin R) Antibody (OX26) - BSA Free [NB200-585]

Flow Cytometry: TfR (Transferrin R) Antibody (OX26) [NB200-585] - An intracellular stain was performed on PC12 cells with TfR (Transferrin R) [OX26] Antibody NB200-585AF647 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 647.

Western Blot: TfR (Transferrin R) Antibody (OX26) - BSA Free [NB200-585] -

Protein level and subcellular content analysis of v-SNARE and Rab proteins in mice crypts. (A) Representative image of 5~50% Optiprep gradient of ep/+ and ep mice small intestine crypts. VAMP7 mainly appears at the 11th and 12th fractions labeled by lysozyme and endosomal component TfR and a second peak appears at the first two fractions labeled by GM130 and TGN38, while it increases in the 4th fraction in ep crypts. Rab38 mainly appears at the first two fractions of both genotypes while its concentration increases in the middle fragments in ep crypts. Rab32 has similar distributional pattern as Rab38 but more widely distributed in 3rd~6th fractions, but less in the 11th fraction labeled by TfR in ep crypts. (B) Statistical analysis of Rab38 distribution in (A). In ep crypt, the increase of Rab38 in the middle density fragments is significant (the 3rd~5th fractions, ep/+ crypts 9%, ep crypts 16%, *p < 0.05). (C) Statistical analysis of Rab32 distribution in (D). Rab32 in ep crypts significantly decreases at the low density fragment (the 1st fraction: ep/+ crypts 25%, ep crypts 16%, *p < 0.05) and at the 9th fraction (ctrl 4%, ep 2%, *p < 0.05). (D) Statistical analysis of VAMP7 distribution in (A). VAMP7 in ep crypts significantly increases in TGN38 and GM130 enriched fraction (the 2nd fraction, ctrl crypts 17%, ep crypts 28%, *p < 0.05) and the 4th fraction (ep/+ crypts 2%, ep crypts 6%, **p < 0.01), and decreases in the RE enriched 11th fraction (ep/+ crypts 18%, ep crypts 5%, *p < 0.05). 4 mice of each genotype were analyzed, values are means +/- s.e.m. of three replicates of immunoblotting data. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/33224134), licensed under a CC-BY license. Not internally tested by Novus Biologicals.